HNR1:XETRHannover Rueck SE Analysis
Data as of 2026-03-11 - not real-time
€248.40
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Hannover Rück is trading at €248.4, just above its near‑term support of €241.6 and modestly below its 20‑day SMA of €249.9, indicating limited upside in the immediate window. The stock benefits from a *PE ratio of 12.1*—well under the industry average of 17.3—combined with a **ROE of over 20%**, a solid dividend yield of 2.84% and a low beta of 0.21, underscoring its defensive profile. Recent headlines confirm a strong earnings beat, a raised earnings target and a 1.5% price lift, while analysts highlight growth avenues in cyber‑risk and natural‑catastrophe reinsurance, pushing the consensus target toward €312.
Given the DCF‑derived fair value of €409 and a modest 14% upside relative to current pricing, the equity appears **undervalued** despite a neutral technical stance (RSI ~49, bearish MACD histogram). The balance sheet is sound with a moderate debt‑to‑equity of 32.5% and a sustainable payout ratio of 34%, supporting confidence in continued dividend payments and long‑term capital appreciation.
Given the DCF‑derived fair value of €409 and a modest 14% upside relative to current pricing, the equity appears **undervalued** despite a neutral technical stance (RSI ~49, bearish MACD histogram). The balance sheet is sound with a moderate debt‑to‑equity of 32.5% and a sustainable payout ratio of 34%, supporting confidence in continued dividend payments and long‑term capital appreciation.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Recent earnings beat and raised target
- Attractive dividend yield with low payout ratio
- Price near support with limited downside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervaluation relative to peers (PE 12 vs 17)
- Growth tailwinds in cyber and natural‑catastrophe lines
- Strong ROE and cash‑flow generation
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustainable dividend backed by solid cash flow
- Robust balance sheet and moderate leverage
- Long‑term secular demand for reinsurance capacity
Key Metrics & Analysis
Financial Health
Revenue Growth-16.10%
Profit Margin8.71%
P/E Ratio12.1
ROE20.55%
ROA3.83%
Debt/Equity32.52
P/B Ratio2.5
Op. Cash Flow€5.3B
Free Cash Flow€3.3B
Industry P/E17.3
Technical Analysis
TrendNeutral
RSI49.1
Support€241.60
Resistance€258.20
MA 20€249.85
MA 50€247.18
MA 200€256.35
MACDBearish
VolumeStable
Fear & Greed Index76.91
Valuation
Fair Value€409.25
Target Price€283.93
Upside/Downside14.30%
GradeUndervalued
TypeBlend
Dividend Yield2.84%
Risk Assessment
Beta0.21
Volatility21.01%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.